subscribeSubscribe
Protagonist Reports Long Term Rusfertide Results At EHA2024 Congress

Protagonist Reports Long Term Rusfertide Results At EHA2024 Congress
ACCESSWIRE
14 Jun 2024
Share Share
Protagonist Presents Rusfertide Phase 2 REVIVE OLE Data At EHA 2024

Protagonist Presents Rusfertide Phase 2 REVIVE OLE Data At EHA 2024
ACCESSWIRE
14 May 2024
Share Share
Protagonist Announces Closing of Worldwide Rusfertide License

Protagonist Announces Closing of Worldwide Rusfertide License
ACCESSWIRE
18 Mar 2024
Share Share
New England Journal of Medicine Publishes Results of Positive Ph 2 of Rusfertide

New England Journal of Medicine Publishes Results of Positive Ph 2 of Rusfertide
ACCESSWIRE
21 Feb 2024
Share Share
Takeda and Protagonist Therapeutics, Inc. Enter into Agreement for Rusfertide

Takeda and Protagonist Therapeutics, Inc. Enter into Agreement for Rusfertide
ACCESSWIRE
31 Jan 2024
Share Share
Protagonist Announces Results from REVIVE Study of Rusfertide

Protagonist Announces Results from REVIVE Study of Rusfertide
ACCESSWIRE
15 Mar 2023
Share Share
FDA seeks to pull Protagonist breakthrough nod over malignancies

FDA seeks to pull Protagonist breakthrough nod over malignancies
N.P. Taylor FIERCEBIOTECH
15 Apr 2022
Share Share
Protagonist posts hormone replacement data in iron disease

Protagonist posts hormone replacement data in iron disease
PRNEWSWIRE
16 Nov 2021
Share Share
Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide

Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide
PRNEWSWIRE
04 Nov 2021
Share Share
Eyes return to the prize for Protagonist’s rusfertide

Eyes return to the prize for Protagonist’s rusfertide
EVALUATE
12 Oct 2021
Share Share